Overview

A Study of RC48-ADC Combined With Triplizumab For Perioperative Treatment of Muscle-Invasive Bladder Cancer

Status:
Not yet recruiting
Trial end date:
2025-02-28
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of intravenous RC48-ADC combined with JS001 in perioperative treatment of muscle-invasive bladder cancer.
Phase:
Phase 2
Details
Lead Sponsor:
RemeGen Co., Ltd.